AveXis (AveXis) Accounts Payable & Accrued Expense : $68.41 Mil (As of Mar. 2018)

View and export this data going back to 2016. Start your Free Trial

What is AveXis Accounts Payable & Accrued Expense?

AveXis's quarterly accounts payable & accrued expense increased from Sep. 2017 ($22.26 Mil) to Dec. 2017 ($48.72 Mil) and increased from Dec. 2017 ($48.72 Mil) to Mar. 2018 ($68.41 Mil).

AveXis's annual accounts payable & accrued expense increased from Dec. 2015 ($6.12 Mil) to Dec. 2016 ($20.60 Mil) and increased from Dec. 2016 ($20.60 Mil) to Dec. 2017 ($48.72 Mil).

AveXis Accounts Payable & Accrued Expense Historical Data

The historical data trend for AveXis's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AveXis Accounts Payable & Accrued Expense Chart

AveXis Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Accounts Payable & Accrued Expense

1.04

5.04

6.12

20.60

48.72

AveXis Quarterly Data
	Dec13	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial										23.71	24.38	22.26	48.72	68.41

AveXis Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

AveXis (AveXis) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AveXis Inc (NAS:AVXS) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.avexis.com

AveXis Inc is a United States-based clinical-stage gene therapy company. It is engaged in developing and commercializing novel treatments for patients suffering from rare and life-threatening neurological genetic diseases. Its product candidate, AVXS-101, is a gene therapy product candidate in Phase 1 clinical trial for the treatment of spinal muscular atrophy, or SMA, Type 1, the genetic cause of infant mortality. AVXS-101 is designed to deliver a fully functional human survival motor neuron gene into the nuclei of motor neurons that then generates an increase in survival motor neuron protein levels. The company believes this will result in improved motor neuron function and patient outcomes.

Executives

Sean P. Nolan	director, officer: President & CEO	C/O INTERMUNE, INC., 3280 BAYSHORE BLVD., BRISBANE CA 94005
Session R.a. Ii	officer: Sr. VP, Corp Strategy	C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 200, BANNOCKBURN IL 60015
Paul B Manning	director, other: Former 10% Owner	200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902
Sukumar Nagendran	officer: Sr. VP & Chief Medical Officer	C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 160, BANNOCKBURN IL 60015
Frank Verwiel	director	C/O INTERMUNE, INC., 3280 BAYSHORE BLVD., BRISBANE CA 94005
James J Litalien	officer: SrVP/Chief Reg&Quality Officer	C/O SOMAXON PHARMACEUTICALS, INC., 3721 VALLEY CENTRE DRIVE, SUITE 500, SAN DIEGO CA 92130
Daniel G Welch	director	4611 UNIVERSITY DR, 4 UNIVERSITY PLACE, DURHAM NC 27707
Rick Modi	officer: Chief Business Officer	C/O AVEXIS INC, 2275 HALF DAY ROAD, SUITE 200, BANNOCKBURN IL 60015
Phillip B. Donenberg	officer: Chief Financial Officer	C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 200, BANNOCKBURN IL 60015
Joao Md Siffert	director	20 ENTERPRISE, SUITE 200, ALISO VIEJO CA 92656
Ag Novartis	10 percent owner	LICHTSTRASSE 35, BASEL V8 CH 4056
Bong Y Koh	director	7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Terrence C Kearney	director	IN CARE OF HOSPIRA, INC., 275 NORTH FIELD DRIVE, LAKE FOREST IL 60045
Deerfield International Master Fund, L.p.	10 percent owner, other: Possible Member of 10% Group	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
James E Flynn	director, 10 percent owner, other: Possible Member of 10% Group	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017